Olaparib was tested in a mono-institutional phase II trial [31] that enrolled patients with either a peritoneal or pleural mesothelioma progressing to first-line treatment and divided them into three cohorts: (1) germline BAP1 mutation, (2) somatic BAP1 mutation or (3) no somatic or germline BAP1 mutations based on NGS results. This evidence concerns the gene BAP1 and pleural mesothelioma.